Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.

@article{Cancello2010PrognosisAA,
  title={Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.},
  author={Giuseppe Cancello and Patrick Maisonneuve and Nicole Rotmensz and Giulia Viale and Mauro Giuseppe Mastropasqua and Giancarlo Pruneri and Paolo Veronesi and Rosalba Torrisi and Emilia Montagna and Alberto Luini and Mattia Intra and Oreste Davide Gentilini and Raffaella Ghisini and Aron Goldhirsch and Marco Colleoni},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 10},
  pages={
          1974-81
        }
}
BACKGROUND There is limited knowledge about prognosis of selected breast cancer subtypes among very young women. PATIENTS AND METHODS We explored patterns of recurrence by age according to four immunohistochemically defined tumor subtypes: Luminal A and Luminal B (estrogen receptor positive and/or progesterone receptor positive and either human epidermal growth factor receptor 2 (HER2) positive and/or high Ki-67), HER2-positive (and) endocrine receptor absent and Triple Negative, in 2970… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 111 CITATIONS, ESTIMATED 58% COVERAGE

Breast cancer in young women : aspects on mortality and local recurrence

VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Biology of breast cancer in young women

VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women

VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2020

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 13 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

VIEW 2 EXCERPTS

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Tamoxifen after adjuvant chemotherapy for premenopausal patients with lymph-node positive breast cancer: International Breast Cancer Study Group Trial 13

  • M Colleoni, S Gelber, A Goldhirsch
  • J Clin Oncol
  • 2006
VIEW 2 EXCERPTS

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.